1) NAME OF THE MEDICINAL PRODUCT

EUROBIOL 25 000 U, gastro-resistant capsule, hard.

2) QUALITATIVE AND QUANTITATIVE COMPOSITION

Porcine pancreas powder* ....274.050 - 329.875 mg
For one capsule.

*Quantity corresponding to an enzymatic activity of
Lipolytic activity ..... 25 000 Ph. Eur. U
Amylolytic activity ..... 22 500 Ph. Eur. U
Proteolytic activity ..... 1 250 Ph. Eur. U
For a full list of excipients, see section 6.1.

3) PHARMACEUTICAL FORM

Gastro-resistant capsule, hard.

4) CLINICAL PARTICULARS

4.1. Therapeutic indications

Treatment of exocrine pancreatic insufficiency in adults and children during:
- cystic fibrosis;
- documented chronic pancreatitis (especially the presence of pancreatic calcifications), in the presence of steatorrhoea ≥ 6 g/24 h;
- cephalic or total pancreatic resections.

4.2. Posology and method of administration

Posology
The optimal posology must be determined and modulated over time depending on diet and patient's digestive status, i.e. number of stools and steatorrhoea.

The usual daily posology is:
- infants until the age of 18 months: 2 capsules
- children: 4 capsules
- adults: 6 capsules

Method of administration
EUROBIOL must be administered in 2 or 3 daily doses, taken during meals.

Capsules can be opened for children who are unable to swallow them and in infants. The granules must not be crunched, but should be administered in a non-alkaline medium (e.g. orange juice) to avoid premature disintegration. Capsules should also be opened in patients with gastrectomy.

Patients must be kept well hydrated, especially during hot weather.

4.3. Contraindications

Not applicable.

4.4. Special warnings and precautions for use

Special warnings
Colonic strictures have been observed in other countries, in children with cystic fibrosis, during the use of high daily doses of pancreatic enzyme replacement therapy, presented in the gastro-resistant form. In all cases, doses were at least 4 times higher than the doses usually recommended in France.

Ensure that steatorrhoea is ≥ 6 g/24 h before prescribing EUROBIOL 25 000 U in patients with documented chronic pancreatitis.

The risk of infectious disease due to transmission of infectious agents cannot be totally excluded during administration of medicinal products containing animal pancreas powder extracts.

These pancreatic extracts may contain porcine parvovirus. However, this virus has not been reported to be transmissible and pathogenic in human.

The detection of porcine parvovirus in pancreas powder extracts can indicate the possible presence of other animal viruses, but no case of transmission of infectious diseases has been reported with these medicinal products, although they have been used for a long time.

The potential viral risk appears to be much lower than the therapeutic benefit of this medicinal product in the indication of documented exocrine pancreatic insufficiency, especially in cystic fibrosis.

Precautions for use
This medicinal product has a high lipase content. In some patients, the dosage must therefore be increased very gradually when initiating treatment due to the risk of severe constipation in case of overdose.

The recommended posology may possibly be increased according to medical prescription and to the severity of exocrine pancreatic insufficiency. However, the posology must never exceed 10 000 units of lipase/kg/day in children (i.e. 0.4 capsule/kg/day; for example: for a 10 kg child, do not exceed a dose of 4 capsules per day), and 250 000 units of lipase/day in adults (i.e. 10 capsules per day).

Hypersensitive subjects to pancreatic extracts may experience gastrointestinal disorders.

Particular caution is advised in cystic fibrosis patients with a history of meconium ileus, bowel resection, or symptoms of belated ileus equivalent.

4.5. Interaction with other medicinal products and other forms of interaction

Not applicable.

4.6. Pregnancy and lactation

Pregnancy:
No reliable animal teratogenesis data are available.
No sufficiently relevant clinical data are currently available to evaluate the possible foetotoxic or malformative effect of EUROBIOL 25 000 U capsules containing gastro-resistant granules when administered during pregnancy.
Eurobiol 25 000 U will be used during pregnancy only if necessary.

Lactation:
No data are available regarding pancreatic extracts passage into breast milk. However, due to the absence of any expected adverse effects in neonates, this medicinal product can be prescribed during breast feeding.

4.7. Effects on ability to drive and use machines

Not applicable.

4.8. Undesirable effects

This medicinal product may induce digestive disorders (constipation) in some patients.

Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: Agence nationale de sécurité du médicament et des produits de santé (Ansm) and réseau des Centres Régionaux de Pharmacovigilance. Website: www.ansm.sante.fr.

4.9. Overdose

Risk of severe constipation in children.

5) PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

ENZYME PREPARATIONS, ATC code: A09AA02.
(A: Digestive tract and metabolism)

The formulation of EUROBIOL in hard gastro-resistant capsules protects pancreatic enzymes from gastric acidity. The enzymatic activity can therefore be released in the duodenum and jejunum.

5.2. Pharmacokinetic properties

Granules remain stable in acid medium for a pH inferior to 5.5. They disintegrate in the duodenum and jejunum.

5.3. Preclinical safety data

Not applicable.

6) PHARMACEUTICAL PARTICULARS

6.1. List of excipients

Microcrystalline cellulose, crospovidone, colloidal anhydrous silica, magnesium stearate, polymethacrylic acid/ethyl acrylate copolymer (1:1), triethyl citrate, talc, simethicone, montanic acid and ethanediol esters (hard paraffin E).

Composition of the capsule shell:
Gelatin, titanium dioxide, red iron oxide, black iron oxide.

6.2. Incompatibilities

Not applicable.

6.3. Shelf-life

Medicinal product in glass bottle: 3 years.
Other containers: 2 years.
After first opening, the product should be used in the next 6 months.

6.4. Special precautions for storage

Do not store above 25°C, protected from moisture.

6.5. Nature and contents of container

100 hard capsules in blisters (PVC/ACLAR/Alu)
Bottle (type III glass) containing 20, 50 or 100 hard capsules.

6.6. Special precautions for disposal and other handling

No special requirements.

7) MARKETING AUTHORISATION HOLDER

LABORATOIRES MAYOLY SPINDLER
6, AVENUE DE L'EUROPE
BP 51
78401 CHATOU CEDEX - France

8) MARKETING AUTHORISATION NUMBER(S)

34009 559 889 3 9: 100 hard capsules in blisters (PVC/ACLAR/Alu)
34009 347 269 1 0: Bottle (type III glass) containing 20 hard capsules
34009 347 271 6 0: Bottle (type III glass) containing 50 hard capsules
34009 395 333 8 4: Bottle (type III glass) containing 100 hard capsules.

9) DATE OF FIRST AUTHORISATION/RENEWAL OF AUTHORISATION

First authorisation: 22 June 1988
Last renewal: 22 June 2008.

10) DATE OF REVISION OF THE TEXT

14 December 2016.

11) DOSIMETRY

Not applicable.

12) INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS

Not applicable.

GENERAL CLASSIFICATION FOR SUPPLY

List I.